Moderna, Inc. $MRNA Shares Purchased by SBI Securities Co. Ltd.

SBI Securities Co. Ltd. raised its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 10.9% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 21,699 shares of the company’s stock after buying an additional 2,138 shares during the quarter. SBI Securities Co. Ltd.’s holdings in Moderna were worth $599,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the stock. S Bank Fund Management Ltd acquired a new stake in shares of Moderna during the first quarter valued at $25,000. TD Private Client Wealth LLC raised its stake in Moderna by 348.8% in the 2nd quarter. TD Private Client Wealth LLC now owns 956 shares of the company’s stock valued at $26,000 after purchasing an additional 743 shares during the last quarter. Atlantic Union Bankshares Corp purchased a new position in Moderna in the 2nd quarter valued at about $26,000. SVB Wealth LLC acquired a new stake in shares of Moderna during the 1st quarter worth about $28,000. Finally, Whittier Trust Co. purchased a new stake in shares of Moderna during the second quarter worth about $28,000. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Trading Down 0.8%

Shares of Moderna stock opened at $24.77 on Friday. The business’s fifty day moving average price is $25.92 and its 200 day moving average price is $27.08. Moderna, Inc. has a twelve month low of $23.04 and a twelve month high of $48.92. The stock has a market capitalization of $9.68 billion, a P/E ratio of -3.07 and a beta of 2.02.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($2.15) by $1.64. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $893.29 million. Moderna had a negative return on equity of 29.81% and a negative net margin of 139.61%.The firm’s revenue was down 45.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.03 earnings per share. Moderna has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Moderna, Inc. will post -9.61 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently issued reports on MRNA shares. Citigroup reduced their price objective on shares of Moderna from $30.00 to $28.00 and set a “neutral” rating on the stock in a research note on Thursday, October 23rd. Leerink Partners reduced their price target on Moderna from $18.00 to $15.00 and set an “underperform” rating on the stock in a research note on Friday, August 22nd. Evercore ISI set a $32.00 price objective on Moderna in a report on Friday, August 1st. Morgan Stanley upped their target price on Moderna from $31.00 to $32.00 and gave the company an “equal weight” rating in a research note on Friday, October 10th. Finally, Barclays decreased their price target on Moderna from $31.00 to $25.00 and set an “equal weight” rating on the stock in a research note on Friday, November 7th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, twelve have issued a Hold rating and four have given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $35.85.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.